Pseudoephedrine citizen petition
This article was originally published in The Tan Sheet
Executive Summary
FDA is "unable to provide a response...at this time" to Pharmacists Planning Service's petition requesting the agency switch pseudoephedrine to a "pharmacists-only" drug class requiring consultation, patient history review, identification and registration for purchase. In a FDL-1letter dated Dec. 9, Center for Drug Evaluation & Research Director Steve Galson, MD, acknowledges failing to provide an answer within FDA's standard 180-day review period, but says the agency will respond "as soon as we have made a decision on your request." PPS, a non-profit advocacy group, submitted the petition June 23 based on claims the drug is used as a performance enhancer, citing its pharmacological relationship to ephedrine (1"The Tan Sheet" Aug. 9, 2004, p. 6)...
You may also be interested in...
Pseudoephedrine Behind-The-Counter Status Sought By Pharmacist Group
A non-profit advocacy group is urging FDA to switch pseudoephedrine products from OTC status to behind-the-counter sale, claiming the drug is being marketed as a performance enhancer
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that of rivals Medicenna were presented at the AACR, suggesting there’s life in the modality yet.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.